Dialysis

CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

Retrieved on: 
Monday, April 8, 2024
Dialysis, Antibiotic, CVC, Infection, Patient, NDA, Taurolidine, Heparin, ARC, FDA, Health, Medical device

CorMedix received NDA approval of DefenCath® under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and expects to begin commercialization of the product in the inpatient setting on April 15th.

Key Points: 
  • CorMedix received NDA approval of DefenCath® under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and expects to begin commercialization of the product in the inpatient setting on April 15th.
  • CorMedix is committed to building meaningful long-term relationships with dialysis providers that are dedicated to innovation and infection reduction.
  • ARC Dialysis, a Miami-based medium-sized dialysis organization, provides inpatient dialysis services to approximately 100 inpatient facilities, and is the operator of 18 outpatient dialysis units throughout Florida.
  • “This agreement with CorMedix for the adoption of DefenCath reinforces our commitment to innovation and patient care, and we are proud of the reputation we’ve established for ourselves as a leading dialysis provider in the southeast United States,” says Fred Dumenigo, CEO of ARC Dialysis.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Community Health, Inc. - CYH

Retrieved on: 
Sunday, March 31, 2024
CYH, Community, Manager, Community health, News, LLP, DOJ, Annual report, Dialysis, Pomerantz

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).
  • The investigation concerns whether Community Health and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
ODD, Research, Hyperphosphatemia, DGF, CRRT, ERA, Administration, Congress, Conference, OLC, CKD, Patient, AKI, National Kidney Foundation, Mitochondrion, NDA, Kidney transplantation, Insurance, Kidney disease, Critical care, Acute kidney injury, Clinical trial, Therapy, Drug development, Safety, Chronic kidney disease, Dialysis, LOS, Research and development, SAD, FDA, KATP, Food, Pharmaceutical industry

LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.
  • Completed a private placement with new and existing healthcare institutional investors that generated $50 million in gross proceeds to Unicycive.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled $9.7 million.
  • Subsequent to year end, in March 2024, Unicycive completed a private placement of preferred stock which generated $50 million in gross proceeds.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Community Health, Inc. - CYH

Retrieved on: 
Saturday, March 23, 2024
Community, Prior, Manager, Community health, News, LLP, DOJ, Annual report, Dialysis, Pomerantz

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).
  • The investigation concerns whether Community Health and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024
Research, Health, Commercialization, Transplant, CKD, Risk, Patient, AHN, Kidney failure, Biostatistics, CBO, Business development, Overalls, Quality of life, Trial of the century, Kidney disease, CVS Health, Clinical trial, EGFR, Chronic kidney disease, Dialysis, Baxter International, Type, Pharmaceutical industry

WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.

Key Points: 
  • WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.
  • In November, the Company announced Dr. Bruce Culleton assumed the role of the CEO and joined the ProKidney board of directors.
  • Dr. Culleton joined ProKidney in July 2023 as Executive Vice President of Clinical Development and Commercialization.
  • Mr. Periera-Kamath had previously joined ProKidney in July 2023 as Vice President of Business Development & Innovative Solutions.

Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed

Retrieved on: 
Wednesday, March 20, 2024
Toxicity, Colchicine, Kidney, Risk, Gout, Patient, Rheumatology, ACR, Diarrhea, Health care, Chronic pain, American College, Dialysis, FDA, Pharmaceutical industry

For patients with severe renal impairment, the starting dose should be 0.3 mg/day.

Key Points: 
  • For patients with severe renal impairment, the starting dose should be 0.3 mg/day.
  • For patients undergoing dialysis, the total recommended dose should be 0.3 mg and be given twice a week.
  • Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
  • For more information on Scilex Holding Company, refer to www.scilexholding.com
    For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

American Kidney Fund Launches Phosphorus Management Education and Awareness Campaign

Retrieved on: 
Tuesday, March 19, 2024
Phosphorus, Hyperphosphatemia, American Kidney Fund, Disease, Education, Patient, Cramp, Kidney failure, Kidney disease, Diet, AKF, Skin, Dialysis, Blood

ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced a new patient-focused educational awareness campaign on managing high phosphorus, also known as hyperphosphatemia.

Key Points: 
  • ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced a new patient-focused educational awareness campaign on managing high phosphorus, also known as hyperphosphatemia.
  • AKF’s phosphorus management education campaign will work to raise awareness among dialysis patients about why phosphorus levels matter, ways to manage phosphorus intake with low phosphorus foods and fluids, and information about existing and new phosphate lowering medications, including phosphate blockers.
  • The campaign will provide people with a host of resources, including a patient-facing education page on AKF’s website; a page on AKF’s nutrition website, Kidney Kitchen ®; downloadable guides on talking to your doctor about phosphorus and low phosphorus foods; and a patient-facing session on hyperphosphatemia management at Kidney Action Week 2024 .
  • We hope that this campaign provides much-needed information to patients and families and can make an impact on their disease management.”

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

Retrieved on: 
Monday, March 18, 2024
Alport syndrome, Diabetic nephropathy, VAR, Institutional review board, Lipid, Patient, Focal segmental glomerulosclerosis, Kidney disease, Fibrosis, Clinical trial, Kidney, Therapy, Chronic kidney disease, Safety, Dialysis, Cholesterol, IRB, Pharmaceutical industry

Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression.

Key Points: 
  • Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression.
  • WESTON, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces Institutional Review Board (IRB) approval of the Phase 2a clinical trial protocol to evaluate the efficacy and safety of Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease.
  • It is the first in human trial for VAR 200 intended to substantiate that the promising preclinical results demonstrated in three different animal models of kidney disease (diabetic kidney disease, focal segmental glomerulosclerosis, and Alport syndrome) translate to patients with kidney disease.
  • We are excited about the potential of Cholesterol Efflux MediatorTM VAR 200 to protect against kidney injury and reduce kidney disease progression.”

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Community Health, Inc. - CYH

Retrieved on: 
Friday, March 15, 2024
CYH, Community, Manager, Community health, News, LLP, DOJ, Annual report, Dialysis, Pomerantz

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Community Health, Inc. (“Community Health” or the “Company”) (NYSE: CYH).
  • The investigation concerns whether Community Health and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Unicycive Announces $50 Million Private Placement

Retrieved on: 
Thursday, March 14, 2024
SVB Securities, Patient, Sale, Kidney disease, Therapy, Dialysis, LOS

The gross proceeds of the private placement are expected to be $50 million, before deducting placement agent fees and other expenses.

Key Points: 
  • The gross proceeds of the private placement are expected to be $50 million, before deducting placement agent fees and other expenses.
  • The private placement is expected to close on March 18, 2024, subject to the satisfaction of customary closing conditions.
  • Leerink Partners and Piper Sandler are acting as placement agents for the private placement.
  • “This financing provides strong validation of the best-in-class potential for our clinical development programs led by Oxylanthanum Carbonate (OLC).